Literature DB >> 21087331

Appropriate and inappropriate electrical therapies delivered by an implantable cardioverter-defibrillator: effect on intracardiac electrogram.

Peter Stempniewicz1, Alan Cheng, Allison Connolly, Xin Yuan Wang, Hugh Calkins, Gordon F Tomaselli, Ronald D Berger, Larisa G Tereshchenko.   

Abstract

INTRODUCTION: Local injury current (LIC) seen after induced ventricular fibrillation rescue implantable cardioverter-defibrillator (ICD) shock predicts heart failure progression. We sought to determine the frequency of LIC after spontaneous events in patients receiving ICD therapies. METHODS AND
RESULTS: Near-field (NF) right ventricular (RV) EGM during 10 seconds after delivered ICD therapy was compared with baseline EGM in 420 events that occurred in 134 patients (mean age 60.8 ± 14.8, 106 [79%] male). The magnitude of elevated or depressed potential immediately after the major fast EGM deflection was defined as LIC, and its ratio to the peak-to-peak EGM amplitude was defined as relative LIC. LIC of at least 1 mV or relative LIC of at least 15% was considered significant. LIC was observed in 121 events (28.8%) and was detected more frequently after appropriate (43 [60.6%] events) and inappropriate (56 [64.4%] events) ICD shocks, as compared with appropriate (8 [9.2%] events) and inappropriate (3 [4.7%] events) antitachycardia pacing (ATP) or nonsustained ventricular tachycardia (11 [9.9%] events) [ANOVA P < 0.0001]. Type of ICD therapy (ICD shock vs ATP) was the most significant predictor of LIC (ATP β coefficient -0.81; 95%CI-1.19 to 0.44); P < 0.0001), along with cycle length of tachycardia (β coefficient -0.0117; 95%CI -0.0167 to -0.0068, P < 0.00001) and shock energy (β coefficient 0.024; 95%CI 0.003-0.045, P = 0.025).
CONCLUSION: Appropriate and inappropriate ICD shocks are frequently characterized by the development of LIC in patients with structural heart disease. Type of electrical ICD therapy, shock energy and cycle length of ventricular arrhythmia are important determinants of LIC.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21087331      PMCID: PMC3093435          DOI: 10.1111/j.1540-8167.2010.01958.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  23 in total

1.  The role of electroporation in defibrillation.

Authors:  A Al-Khadra; V Nikolski; I R Efimov
Journal:  Circ Res       Date:  2000-10-27       Impact factor: 17.367

Review 2.  Implantable cardioverter-defibrillators.

Authors:  John P DiMarco
Journal:  N Engl J Med       Date:  2003-11-06       Impact factor: 91.245

3.  Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction.

Authors:  Norman C Wang; Jonathan P Piccini; Marvin A Konstam; Aldo P Maggioni; Brian Traver; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; Christopher M O'Connor; Alan B Miller; Liliana Grinfeld; Mihai Gheorghiade
Journal:  Am J Ther       Date:  2010 Jul-Aug       Impact factor: 2.688

4.  Current of injury predicts adequate active lead fixation in permanent pacemaker/defibrillation leads.

Authors:  Sherry J Saxonhouse; Jamie B Conti; Anne B Curtis
Journal:  J Am Coll Cardiol       Date:  2005-02-01       Impact factor: 24.094

5.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

6.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

7.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

8.  Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.

Authors:  Arthur J Moss; Henry Greenberg; Robert B Case; Wojciech Zareba; W Jackson Hall; Mary W Brown; James P Daubert; Scott McNitt; Mark L Andrews; Adam D Elkin
Journal:  Circulation       Date:  2004-12-06       Impact factor: 29.690

9.  Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results.

Authors:  Mark S Wathen; Paul J DeGroot; Michael O Sweeney; Alice J Stark; Mary F Otterness; Wayne O Adkisson; Robert C Canby; Koroush Khalighi; Christian Machado; Donald S Rubenstein; Kent J Volosin
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

Review 10.  Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection.

Authors:  Andrew P Halestrap; Samantha J Clarke; Sabzali A Javadov
Journal:  Cardiovasc Res       Date:  2004-02-15       Impact factor: 10.787

View more
  1 in total

1.  Dynamic analysis of cardiac rhythms for discriminating atrial fibrillation from lethal ventricular arrhythmias.

Authors:  Deeptankar DeMazumder; Douglas E Lake; Alan Cheng; Travis J Moss; Eliseo Guallar; Robert G Weiss; Steven R Jones; Gordon F Tomaselli; J Randall Moorman
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.